Work

Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities

Year: 2008

Type: article

Study design: Clinical Trial

Source: CHEST Journal

DOI: 10.1378/chest.08-1028

Authors: Michael D. McGoon, Adaani E. Frost, Ronald J. Oudiz, David B. Badesch, Nazzareno Galie, Horst Olschewski, Vallerie V. McLaughlin, Michael J. Gerber, Chris Dufton, Darrin J. Despain, Lewis J. Rubin

Institutions: Mayo Clinic, Baylor College of Medicine, The Lundquist Institute, Harbor–UCLA Medical Center, University of Colorado Denver, University of Bologna, Medical University of Graz, University of Michigan, Gilead Sciences (United States), University of California San Diego

Language: English

Topic: Pulmonary Hypertension Research and Treatments

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2101437558

FWCI: 18.94

Cites: 18

Cited by: 189

Related to: 10